Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATEV for Vascular Replacement or Reconstruction in Vascular Trauma
NCT03005418Phase 3Completed
- Sponsor
- Humacyte
- Start
- Sep 2018
- Primary completion
- Sep 2023
- Modality
- Device-based Delivery, Tissue Cells, Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of acellular tissue engineered vessel in vascular trauma, sponsored by Humacyte. Primary endpoint: Primary Patency Rate of the Human Acellular Vessel (HAV) at 36 months. Started Sep 2018; status: completed.
02
Drugs
acellular tissue engineered vessel
03
Conditions
vascular trauma
Beyond the preview
Go deeper on NCT03005418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005418.